Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

Prana Biotechnology Investor Presentation

June 27, 2018August 16, 2022 Alterity Therapeutics

1_Prana Biotechnology Investor Presentation_2018-0627 final

2018

Post navigation

Prana to commence Phase 1 clinical trial of PBT434 for treatment of parkinsonian diseases

First volunteers dosed in Phase I clinical trial of PBT434, Prana’s lead therapy for parkinsonian diseases

Related Posts

Dr David Stamler’s Biotech Showcase Presentation

January 7, 2019August 16, 2022

EMA publishes minutes recommending Orphan Drug Designation for PBT2

May 21, 2015August 16, 2022

XBRL 30 June 2024 filed with the SEC

September 30, 2024September 30, 2024

Recent Posts

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy
Appendix 4C – Q2 FY25 Quarterly Cash Flow Report
Alterity Therapeutics Issues Shareholder Newsletter Highlighting Pipeline Advances and Key Upcoming Milestones
Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy
Chairman’s Address 2024 Annual General Meeting

Recent Comments

Archives

Archives

Categories

ASX Announcements
Chairman's Address
Investor Announcement

Tags

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

LinkedIn
Facebook
X

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065